BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9619838)

  • 1. Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts.
    Kilbey A; Bartholomew C
    Oncogene; 1998 Apr; 16(17):2287-91. PubMed ID: 9619838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation.
    Bartholomew C; Kilbey A; Clark AM; Walker M
    Oncogene; 1997 Feb; 14(5):569-77. PubMed ID: 9053855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence.
    Kurokawa M; Ogawa S; Tanaka T; Mitani K; Yazaki Y; Witte ON; Hirai H
    Oncogene; 1995 Sep; 11(5):833-40. PubMed ID: 7675444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solution structure of a Zap1 zinc-responsive domain provides insights into metalloregulatory transcriptional repression in Saccharomyces cerevisiae.
    Wang Z; Feng LS; Matskevich V; Venkataraman K; Parasuram P; Laity JH
    J Mol Biol; 2006 Apr; 357(4):1167-83. PubMed ID: 16483601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UXT interacts with the transcriptional repressor protein EVI1 and suppresses cell transformation.
    McGilvray R; Walker M; Bartholomew C
    FEBS J; 2007 Aug; 274(15):3960-71. PubMed ID: 17635584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG.
    Funabiki T; Kreider BL; Ihle JN
    Oncogene; 1994 Jun; 9(6):1575-81. PubMed ID: 8183551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional repression by the proto-oncogene BCL-6.
    Seyfert VL; Allman D; He Y; Staudt LM
    Oncogene; 1996 Jun; 12(11):2331-42. PubMed ID: 8649773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
    Mitani K
    Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evi-1 zinc finger myeloid transforming protein binds to genomic fragments containing (GATA)n sequences.
    Matsugi T; Kreider BL; Delwel R; Cleveland JL; Askew DS; Ihle JN
    Oncogene; 1995 Jul; 11(1):191-8. PubMed ID: 7624127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
    Nitta E; Izutsu K; Yamaguchi Y; Imai Y; Ogawa S; Chiba S; Kurokawa M; Hirai H
    Oncogene; 2005 Sep; 24(40):6165-73. PubMed ID: 15897867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins.
    Palmer S; Brouillet JP; Kilbey A; Fulton R; Walker M; Crossley M; Bartholomew C
    J Biol Chem; 2001 Jul; 276(28):25834-40. PubMed ID: 11328817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
    Kurokawa M; Mitani K; Irie K; Matsuyama T; Takahashi T; Chiba S; Yazaki Y; Matsumoto K; Hirai H
    Nature; 1998 Jul; 394(6688):92-6. PubMed ID: 9665135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
    Kurokawa M; Mitani K; Yamagata T; Takahashi T; Izutsu K; Ogawa S; Moriguchi T; Nishida E; Yazaki Y; Hirai H
    EMBO J; 2000 Jun; 19(12):2958-68. PubMed ID: 10856240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of human ZNF274 cDNA, which encodes a novel kruppel-type zinc-finger protein having nucleolar targeting ability.
    Yano K; Ueki N; Oda T; Seki N; Masuho Y; Muramatsu M
    Genomics; 2000 Apr; 65(1):75-80. PubMed ID: 10777669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes.
    Morishita K; Parganas E; Parham DM; Matsugi T; Ihle JN
    Oncogene; 1990 Sep; 5(9):1419-23. PubMed ID: 1699199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC.
    Morishita K; Suzukawa K; Taki T; Ihle JN; Yokota J
    Oncogene; 1995 May; 10(10):1961-7. PubMed ID: 7761097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional domains of the TGF-beta-inducible transcription factor Tieg3 and detection of two putative nuclear localization signals within the zinc finger DNA-binding domain.
    Spittau B; Wang Z; Boinska D; Krieglstein K
    J Cell Biochem; 2007 Jun; 101(3):712-22. PubMed ID: 17252542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAF(II)110.
    Cohen SB; Nicol R; Stavnezer E
    Oncogene; 1998 Nov; 17(19):2505-13. PubMed ID: 9824161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
    Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.